Polycythemia Vera Drug Sales Market Report
SPECIAL OFFER : 25% Super Discount For All !
Global Polycythemia Vera Drug Sales Market, By Type (Dasatinib, Idelalisib, Givinostat, M-009, and Others), By Application (Clinic, Hospital, Others), By Region (North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle-East & Africa (MEA) Trend Analysis, Competitive Market Share & Forecast, 2017-2027
- Published Date: August 2021
- Report ID: BWC20359
- Available Format: PDF
- Page: 141
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Research Methodology
2.1. Qualitative Research
2.1.1. Primary and Secondary Sources
2.2. Quantitative Research
2.2.1. Primary and Secondary Sources
2.3. Breakdown of Primary Research Respondents
2.3.1. Secondary Research
2.3.2. Primary Research
2.4. Breakdown of Primary Research Respondents, By Industry Participants
2.5. Key Questionnaire asked during Primary Interviews
2.6. Key Primary Responses
2.7. Market Size Estimation
2.8. Assumption for the Study
2.9. Market Breakdown & Data Triangulation
3. Executive Summary
4. Global Polycythemia Vera Drug Sales Market – Industry Insights
4.1. DROC Analysis
4.1.1. Growth Drivers
4.1.2. Restraints
4.1.3. Opportunity
4.1.4. Challenges
4.2. Recent Developments / Technical Landscape
4.3. Regulatory Framework
4.4. Porter’s Five Forces Analysis
4.5. Value Chain Analysis
4.6. PESTEL Analysis
4.7. Strategic Outlook
5. Global Polycythemia Vera Drug Sales Market Overview
5.1. Market Estimates & Forecast by Value, 2017-2027
5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
5.2.1.1. Datatinib
5.2.1.2. Idelalisib
5.2.1.3. Givinostat
5.2.1.4. M-009
5.2.1.5. Others
5.2.2. By Application
5.2.2.1. Clinic
5.2.2.2. Hospital
5.2.2.3. Others
5.2.3. By Region
5.2.3.1. North America
5.2.3.2. Europe
5.2.3.3. Asia-Pacific (APAC)
5.2.3.4. Latin America (LATAM)
5.2.3.5. Middle-East & Africa (MEA)
6. North America Polycythemia Vera Drug Sales Market Overview
6.1. Market Size and Forecast
6.1.1. By Value (USD Million), 2017-2027
6.2. Market Share and Forecast
6.2.1. By Type
6.2.2. By Application
6.2.3. By Country
6.2.3.1. U.S.
6.2.3.2. Canada
7. Europe Polycythemia Vera Drug Sales Market Overview
7.1. Market Size and Forecast
7.1.1. By Value (USD Million), 2017-2027
7.2. Market Share and Forecast
7.2.1. By Type
7.2.2. By Application
7.2.3. By Country
7.2.3.1. Germany
7.2.3.2. U.K.
7.2.3.3. France
7.2.3.4. Italy
7.2.3.5. Spain
7.2.3.6. Russia
7.2.3.7. Netherlands
7.2.3.8. Rest of Europe
8. APAC Polycythemia Vera Drug Sales Market Overview
8.1. Market Size and Forecast
8.1.1. By Value (USD Million), 2017-2027
8.2. Market Share and Forecast
8.2.1. By Type
8.2.2. By Application
8.2.3. By Country
8.2.3.1. China
8.2.3.2. India
8.2.3.3. Japan
8.2.3.4. South Korea
8.2.3.5. Rest of APAC
9. LATAM Polycythemia Vera Drug Sales Market Overview
9.1. Market Size and Forecast
9.1.1. By Value (USD Million), 2017-2027
9.2. Market Share and Forecast
9.2.1. By Type
9.2.2. By Application
9.2.3. By Country
9.2.3.1. Mexico
9.2.3.2. Brazil
9.2.3.3. Rest of LATAM
10.MEA Polycythemia Vera Drug Sales Market Overview
10.1. Market Size and Forecast
10.1.1. By Value (USD Million), 2017-2027
10.2. Market Share and Forecast
10.2.1. By Type
10.2.2. By Application
10.2.3. By Country
10.2.3.1. Saudi Arabia
10.2.3.2. UAE
10.2.3.3. South Africa
10.2.3.4. Rest of Europe
11.Competitive Landscape
11.1.1. List of Key Producers and Their Offerings
11.1.2. Market Share / Ranking Analysis (2020)
11.1.3. Competitive Benchmarking, By Operating Parameters
12.COVID-19 Impact
12.1. Future Impact
12.2. Key Developments during COVID-19
12.3. Impact on Market
12.3.1. Different Scenario
12.3.2. Impact on Companies
12.4. Regional Impact
13.Key Strategic Recommendations
14.Company Profiles (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *
14.1. ANP Technologies, Inc.
14.2. Bristol-Myers Squibb Company
14.3. F. Hoffmann-La Roche Ltd.
14.4. Galena Biopharma, Inc.
14.5. Gilead Sciences, Inc.
14.6. Italfarmaco S.p.A.
14.7. Karus Therapeutics Limited
14.8. miRagen Therapeutics, Inc.
14.9. Nerviano Medical Sciences S.r.l.
14.10. Novartis AG
14.11. PharmaEssentia Corporation
14.12. Teva Pharmaceutical Industries Ltd.
14.13. Otsuka America Pharmaceutical
14.14. Inc. Pharmaclon
14.15. Alfarm
14.16. GNC Vector
14.17. Zydus Cadila Incyte Corp.
14.18. Pfizer
14.19. Eli Lilly and Company
14.20. Other Prominent Players
RELATED REPORTS
WHY CHOOSE US
-
24/7 Research Support
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
-
Custom Research Service
Ask the Analyst to customize an exclusive study to serve your research needs
-
Quality & Accuracy
Ask the Analyst to customize an exclusive study to serve your research needs
-
Data Visualization
As the business world is changing dynamically every day. We need to stay pin point in relation to data management and optimum data utilization
-
Information security
We never share your personal and confidential information. Your personal information is safe and secure with us.